Public Companies
How The 5 Cannabis Categories Performed Last Week
The 5 categories in the cannabis sector perform quite differently from each other on a weekly basis and below is a summary of how each category performed…
The 5 categories in the cannabis sector perform quite differently from each other on a weekly basis and below is a summary of how each category performed last week, in descending order, and YTD.
An original article by Lorimer Wilson, Managing Editor of munKNEE.com – Your KEY To Making Money!
- The Ancillary Pot Stock Index: UP 12.0% last week; UP 16.8% YTD
- The Index consists of the 7 largest companies providing goods and services to the cannabis sector, namely, AFC Gamma (AFCG); Forian (FORA); Hydrofarm (HYFM); GrowGeneration (GRWG); Innovative Industrial Properties (IIPR); Scotts Miracle-Gro Company (SMG) and Turning Point Brands (TPB) which trade for at least US$3/share on the Canadian and/or American stock exchanges and have a market cap of at least US$100M.
- The American Cannabis MSOs Index: UP 7.3% last week; UP 2.0% YTD
- The Index consists of the 12 largest American Multi-State Operators, namely, Acreage (ACRDF/ACRHF); Ascend Wellness (AAWH); Ayr Wellness (AYRWF); Columbia Care (CCHWF); Cresco (CRLBF); Curaleaf (CURLF); Green Thumb (GTBIF); Jushi (JUSHF); Planet 13 (PLNHF); TerrAscend (TRSSF); Trulieve (TCNNF) and Verano (VRNOF) which trade for at least US$1/share on the Canadian and/or American stock exchanges and have a market cap of at least US$200M.
- Read: 12 Largest American Cannabis MSO Stocks Up 7% This Week
- The Conservative Pot Stocks Index: UP 1.8% last week; UP 0.1% YTD
- The Index consists of 6 tobacco, beer, and liquor companies that have invested heavily in the cannabis industry, namely, Altria Group (MO); Anheuser-Busch (BUD); British American Tobacco (BTI); Constellation Brands (STZ); Imperial Brands (IMBBY) and Molson Coors Brewing Company (TAP) and they all pay dividends with yields ranging from just 0.9% for Anheuser Busch to 8.4% for Altria and average out at 3.1%.
- The Canadian Cannabis LPs Index; UP 0.1% last week; UP 15.9% YTD
- The Index consists of the 5 largest Canadian Licensed Producers, namely: Aurora (ACB); Canopy Growth (CGC); Cronos (CRON); Organigram (OGI), and Tilray (TLRY) which trade for at least US$1/share on the Canadian and/or American stock exchanges and have a market cap in excess of US$250M.
- Read: 5 Largest Canadian Cannabis Stocks Flat This Week
- The Psychedelic Drug Stocks Index: DOWN 2.9% last week; UP 12.8% YTD
- The Index consists of 6 psychedelic compound-based and marijuana (THC) drug companies in the clinical stages of research and development of treatments for a wide variety of mental illnesses, namely, Cybin (CYBN); Atai (ATAI); Seelos (SEEL), Compass Pathway (CMPS); Mind Medicine (MNMD) and GH Resources (GHRS) which trade on the Canadian and/or American stock exchanges and have market caps of at least US$50M.
- Read; 6 Largest Psychedelic Stocks Down 3% This Week
In summary, the 5 cannabis/cannabis-related company stock category performances ranged from:
- +12.0% to -2.9% last week, and are now
- +16.8% to +0.1% YTD.
-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics7 days ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics7 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics7 days ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference